Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography

Authors:

Abstract
Alzheimer disease (AD) includes a decades-long period of pathologic changes leading to dementia onset.1,2 To improve and rationalize the early detection of disease, the AD community is considering a biology-based disease classification relying principally on evidence of characteristic AD amyloid-β (Aβ) and tau pathologies.3 Such evidence can come from analysis of cerebrospinal fluid (CSF) or positron emission tomography (PET). Because these modalities are not typically available simultaneously, their results are often used interchangeably. However, CSF and PET indicators of Aβ pathology appear to provide overlapping, but not identical, information.4,5 Thus, some have suggested that CSF Aβ abnormality may precede Aβ-PET positivity.6 Discordance of these 2 biomarker measures may therefore indicate different stages of disease progression.

This publication has 44 references indexed in Scilit: